Loading stock data…
TELA
$0.99+0.11 (+13.07%)
Market ClosedLast close May 1
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
TELA Bio, Inc. in the Healthcare sector is trading at $0.99. The stock is currently 55% below its 52-week high of $2.20, remaining 17.6% below its 200-day moving average. Technical signals show overbought RSI of 81 and bullish MACD crossover, explaining why TELA maintains its current current market pressure. The Whystock Score of 0/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 81) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.99
Potential Upside
5%
Whystock Fair Value$1.04
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$27.94M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.99
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-615.10%
Volume
Today's trading volume
974,588
Recent News
TELA Bio, Inc. Q4 2025 Earnings Call Summary
Moby summary of TELA Bio, Inc.'s Q4 2025 earnings call
TELA Bio Inc (TELA) Q4 2025 Earnings Call Highlights: Record Revenue Growth Amid Strategic ...
Despite a challenging year with significant organizational changes, TELA Bio Inc (TELA) achieved a 16% revenue growth in 2025, setting the stage for future expansion.
TELA Bio (TELA) Q4 2025 Earnings Call Transcript
Antony Koblish: Thank you, Louisa, and good afternoon. Thank you for joining TELA Bio, Inc.'s fourth quarter and full year 2025 earnings call. Jeffrey will then walk through the foundational changes implemented in the commercial organization and how we anticipate they will impact our future performance.
TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates
TELA Bio (TELA) delivered earnings and revenue surprises of +11.11% and -0.62%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Assembly Biosciences (ASMB) Q4 Earnings and Revenues Top Estimates
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of +586.28% and +300.65%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?